<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063854</url>
  </required_header>
  <id_info>
    <org_study_id>CCT-401</org_study_id>
    <secondary_id>JapicCTI-142440</secondary_id>
    <secondary_id>U1111-1153-0440</secondary_id>
    <secondary_id>NE-58095DR/CCT-401</secondary_id>
    <nct_id>NCT02063854</nct_id>
    <nct_alias>NCT02066376</nct_alias>
  </id_info>
  <brief_title>A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets</brief_title>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present phase II/III, multicenter, randomized, double-blind, parallel group comparative
      study is designed to evaluate the efficacy and safety of once-monthly oral administration of
      NE-58095 delayed release (DR) tablets for 12 months in participants with involutional
      osteoporosis. For this study, participants receiving oral NE-58095 immediate release (IR) 2.5
      mg tablets once daily for 12 months are set as the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the present study is to verify the non-inferiority of once-monthly
      oral administration of NE-58095 DR tablets for 12 months to once-daily oral administration of
      NE-58095 IR 2.5 mg tablets for 12 months, in terms of efficacy in participants with
      involutional osteoporosis.

      Secondary objectives of the present study are as follows: to compare the safety of
      once-monthly oral administration of NE-58095 DR tablets for 12 months with the safety of
      once-daily oral administration of NE-58095 IR tablets (at 2.5 mg) for 12 months in
      participants with involutional osteoporosis at time of wakening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study</measure>
    <time_frame>Baseline and End of Study (up to Month 12)</time_frame>
    <description>The change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) BMD Measured by DXA at Each Visit</measure>
    <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>The change in BMD in each vertebra, L2 to L4, and the averages of L2 to L4 at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femur (Total Proximal Femur) BMD Measured by DXA at Each Visit</measure>
    <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>The change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femur (Trochanter) BMD Measured by DXA at Each Visit</measure>
    <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>The change in BMD in the femur (trochanter) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femur (Femoral Neck) BMD Measured by DXA at Each Visit</measure>
    <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>The change in BMD in the femur (femoral neck) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Turnover Marker Serum Creatinine (CTX) at Each Visit</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Turnover Marker Serum Bone-type Alkaline Phosphatase (BAP) at Each Visit</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Turnover Marker Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Each Visit</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Turnover Marker Serum Procollagen 1 N-terminal Peptide (P1NP) at Each Visit</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Turnover Marker Urine Type 1 Collagen Cross-linked N-telopeptide (NTX) at Each Visit</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
    <description>Urine samples for urine bone turnover markers were collected at specified visits according to the study schedule. Urine samples were to be collected at about the same time of the day, as far as possible, throughout the study. Urine NTX was corrected by creatinine value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Non-traumatic Vertebral Fractures (Including the Worsening of Pre-existing Fractures)</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>New non-traumatic vertebral fractures were identified by interpretable X-ray images of 13 vertebrae from the fourth thoracic to the fourth lumbar vertebra. A Central Review Committee member for X-ray determined the presence or absence of new vertebral fractures, the number of new fractures, the presence or absence of worsening pre-existing vertebral fractures, and the number of worsened fractures. The assessment of new vertebral fractures and the worsening of pre-existing vertebral fractures was semiquantitative. The X-ray images were visually inspected and classified into normal (Grade 0), mild deformation (Grade 1), moderate deformation (Grade 2), or severe deformation (Grade 3). If the assessment of any vertebra became worse by at least 1 grade after starting the treatment, its height was measured. A new vertebral fracture or a worsening pre-existing vertebral fracture was concluded if the vertebra's height was reduced from the baseline by at least 20% and by at least 4 mm.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">871</enrollment>
  <condition>Involutional Osteoporosis</condition>
  <arm_group>
    <arm_group_label>NE-58095 IR 2.5 mg Once Daily on Awakening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NE-58095 IR</intervention_name>
    <description>NE-58095 IR tablets</description>
    <arm_group_label>NE-58095 IR 2.5 mg Once Daily on Awakening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NE-58095 IR Placebo</intervention_name>
    <description>NE-58095 IR placebo-matching tablets</description>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NE-58095 DR</intervention_name>
    <description>NE-58095 DR tablets</description>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NE-58095 DR Placebo</intervention_name>
    <description>NE-58095 DR placebo-matching tablets</description>
    <arm_group_label>NE-58095 IR 2.5 mg Once Daily on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly on Awakening</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</arm_group_label>
    <arm_group_label>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of involutional osteoporosis

          2. Male or female outpatients (including patients admitted to the hospital for tests)
             aged ≥ 50 years at the time of consent

          3. Women for whom at least 2 years have passed since the last natural menstruation

        Exclusion Criteria:

          1. Patients with secondary osteoporosis

          2. Patients with diseases (other than secondary osteoporosis) that present with decreased
             bone mass

          3. Patients with findings that affects the measurement of mean bone mineral density of
             the lumbar spine by dual-energy X-ray absorptiometry (DXA)

          4. Patients with a history of radiotherapy to the lumbar spine or the pelvis

          5. Patients who are planning to receive surgical dental procedures such as tooth
             extraction (including dental implant treatment) during the treatment period

          6. Patients with a history of treatment with any anti-receptor activator of nuclear
             factor-κB ligand (RANKL) monoclonal antibodies or parathyroid hormone products within
             1 year before the start of the treatment period

          7. Patients with a history of treatment with any bisphosphonate products within 24 weeks
             before the start of the treatment period

          8. Patients who have received any drugs that affect bone metabolism within 8 weeks before
             the start of the treatment period

          9. Patients with disorders such as esophagitis, peptic ulcer (e.g., esophageal ulcer,
             gastric ulcer, and duodenal ulcer), or gastrointestinal bleeding

         10. Patients with disorders that delay esophageal emptying (e.g., dysphagia,
             esophagostenosis, or achalasia of the esophagus)

         11. Patients with hypocalcemia

         12. Patients with hypercalcemia

         13. Patients with a diagnosis of renal calculus

         14. Patients with serious renal, hepatic, or cardiac disease

         15. Patients who have received surgical dental procedures, such as a tooth extraction
             (including dental implant treatment), but whose dental problems remain unresolved at
             the start of the treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Narashino-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Onga-gun</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ebetsu-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kako-gun</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atsugi-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zushi-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamana-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tagajo-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saito-shi</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashi Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daito-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 67 investigative sites in Japan from 21 February 2014 to 19 November 2015.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of involutional osteoporosis were randomized at a ratio of 3:1:3:1:1:3:1 into 1 of 7 treatment groups: once-daily NE-58095 2.5 mg immediate release (IR) or once-monthly NE-58095 25 mg or 37.5 mg delayed release (DR) on awakening, after breakfast or 30 minutes following breakfast.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
          <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P2">
          <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P3">
          <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P4">
          <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P5">
          <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P6">
          <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="P7">
          <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="201"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set: Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="200"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="176"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="54"/>
                <participants group_id="P6" count="170"/>
                <participants group_id="P7" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgical Dental Work Performed/Planned</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set included all participants who were randomized to the study.</population>
      <group_list>
        <group group_id="B1">
          <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
          <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B2">
          <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B3">
          <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B4">
          <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B5">
          <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B6">
          <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B7">
          <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="199"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="201"/>
            <count group_id="B7" value="66"/>
            <count group_id="B8" value="871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="7.32"/>
                    <measurement group_id="B2" value="69.0" spread="8.18"/>
                    <measurement group_id="B3" value="68.2" spread="7.68"/>
                    <measurement group_id="B4" value="68.4" spread="7.24"/>
                    <measurement group_id="B5" value="69.0" spread="6.98"/>
                    <measurement group_id="B6" value="69.6" spread="7.19"/>
                    <measurement group_id="B7" value="69.8" spread="7.87"/>
                    <measurement group_id="B8" value="68.9" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="198"/>
                    <measurement group_id="B7" value="63"/>
                    <measurement group_id="B8" value="847"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="201"/>
                    <measurement group_id="B7" value="66"/>
                    <measurement group_id="B8" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152.1" spread="6.59"/>
                    <measurement group_id="B2" value="151.0" spread="6.64"/>
                    <measurement group_id="B3" value="151.9" spread="6.11"/>
                    <measurement group_id="B4" value="152.5" spread="5.49"/>
                    <measurement group_id="B5" value="153.5" spread="5.13"/>
                    <measurement group_id="B6" value="151.3" spread="5.20"/>
                    <measurement group_id="B7" value="151.9" spread="6.47"/>
                    <measurement group_id="B8" value="151.9" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.52" spread="7.975"/>
                    <measurement group_id="B2" value="49.98" spread="6.720"/>
                    <measurement group_id="B3" value="50.20" spread="7.231"/>
                    <measurement group_id="B4" value="50.97" spread="8.736"/>
                    <measurement group_id="B5" value="51.26" spread="7.473"/>
                    <measurement group_id="B6" value="50.36" spread="7.383"/>
                    <measurement group_id="B7" value="50.51" spread="7.427"/>
                    <measurement group_id="B8" value="50.46" spread="7.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.82" spread="3.009"/>
                    <measurement group_id="B2" value="21.93" spread="2.830"/>
                    <measurement group_id="B3" value="21.75" spread="2.926"/>
                    <measurement group_id="B4" value="21.97" spread="3.875"/>
                    <measurement group_id="B5" value="21.79" spread="3.289"/>
                    <measurement group_id="B6" value="22.00" spread="3.105"/>
                    <measurement group_id="B7" value="21.90" spread="3.071"/>
                    <measurement group_id="B8" value="21.87" spread="3.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="168"/>
                    <measurement group_id="B7" value="58"/>
                    <measurement group_id="B8" value="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <description>Female participants only (N=190, 64, 203, 66, 63, 198, 63).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Natural Menopause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="180"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Artificial Menopause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Years After Menopause, Categorical</title>
          <description>Female participants only (N=190, 64, 203, 66, 63, 198, 63).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Min - ≤5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - ≤10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 - ≤20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 - ≤30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥31 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown, But &gt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Years After Menopause</title>
          <description>Data was available for 152, 52, 159, 56, 54, 162 and 51 female participants in each treatment arm, respectively.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="7.81"/>
                    <measurement group_id="B2" value="20.2" spread="8.72"/>
                    <measurement group_id="B3" value="17.2" spread="8.44"/>
                    <measurement group_id="B4" value="18.3" spread="8.28"/>
                    <measurement group_id="B5" value="19.2" spread="8.36"/>
                    <measurement group_id="B6" value="19.5" spread="8.41"/>
                    <measurement group_id="B7" value="20.1" spread="7.84"/>
                    <measurement group_id="B8" value="18.7" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Bisphosphonate Administration</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="175"/>
                    <measurement group_id="B7" value="60"/>
                    <measurement group_id="B8" value="773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timing of Initial Delayed Release (DR) Tablet Administration on Awakening</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 30 Minutes before Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 to 1.5 Hours before Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="164"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 to 2.5 Hours before Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 to 4 Hours before Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar Spine (L2-L4) Bone Mineral Density (BMD), Categorical</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively. YAM=young adult mean (20 to 44 years age range).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Min - ≤0.707 g/cm^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="158"/>
                    <measurement group_id="B7" value="49"/>
                    <measurement group_id="B8" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.708 (70%YAM) - ≤0.808 g/cm^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.809 (80%YAM) g/cm^2 - ≤Max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>L2-L4 (BMD)</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6553" spread="0.09060"/>
                    <measurement group_id="B2" value="0.6690" spread="0.11746"/>
                    <measurement group_id="B3" value="0.6477" spread="0.08037"/>
                    <measurement group_id="B4" value="0.6633" spread="0.08766"/>
                    <measurement group_id="B5" value="0.6448" spread="0.08909"/>
                    <measurement group_id="B6" value="0.6589" spread="0.09893"/>
                    <measurement group_id="B7" value="0.6714" spread="0.09999"/>
                    <measurement group_id="B8" value="0.6564" spread="0.09303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>L2-L4 BMD T-score, Categorical</title>
          <description>BMD T-score is a comparison of an individual's BMD compared to &quot;normal&quot;. Also, BMD T-score is the standard deviation of the difference between measured BMD and that of the healthy young adult &quot;normal&quot;. The T-score scale is as follows: -1 and above=normal, -1 to -2.5=osteopenia (below normal and may lead to osteoporosis), and -2.5 and below=osteoporosis.
Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Min - ≤-2.500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="160"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-2.499 - ≤-1.000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.999 - ≤Max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>L2-L4 BMD T-score</title>
          <description>BMD T-score is a comparison of an individual's BMD compared to &quot;normal&quot;. Also, BMD T-score is the standard deviation of the difference between measured BMD and that of the healthy young adult &quot;normal&quot;. The T-score scale is as follows: -1 and above=normal, -1 to -2.5=osteopenia (below normal and may lead to osteoporosis), and -2.5 and below=osteoporosis. Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.9889" spread="0.76130"/>
                    <measurement group_id="B2" value="-2.8738" spread="0.98709"/>
                    <measurement group_id="B3" value="-3.0532" spread="0.67537"/>
                    <measurement group_id="B4" value="-2.9219" spread="0.73670"/>
                    <measurement group_id="B5" value="-3.0773" spread="0.74863"/>
                    <measurement group_id="B6" value="-2.9587" spread="0.83135"/>
                    <measurement group_id="B7" value="-2.8536" spread="0.84030"/>
                    <measurement group_id="B8" value="-2.9796" spread="0.78178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Proximal Femur BMD</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6553" spread="0.08997"/>
                    <measurement group_id="B2" value="0.6573" spread="0.09537"/>
                    <measurement group_id="B3" value="0.6452" spread="0.08490"/>
                    <measurement group_id="B4" value="0.6580" spread="0.07982"/>
                    <measurement group_id="B5" value="0.6486" spread="0.06973"/>
                    <measurement group_id="B6" value="0.6652" spread="0.08465"/>
                    <measurement group_id="B7" value="0.6520" spread="0.07289"/>
                    <measurement group_id="B8" value="0.6548" spread="0.08464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Proximal Femur BMD T-score</title>
          <description>BMD T-score is a comparison of an individual's BMD compared to &quot;normal&quot;. Also, BMD T-score is the standard deviation of the difference between measured BMD and that of the healthy young adult &quot;normal&quot;. The T-score scale is as follows: -1 and above=normal, -1 to -2.5=osteopenia (below normal and may lead to osteoporosis), and -2.5 and below=osteoporosis. Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.1972" spread="0.89971"/>
                    <measurement group_id="B2" value="-2.1770" spread="0.95369"/>
                    <measurement group_id="B3" value="-2.2982" spread="0.84903"/>
                    <measurement group_id="B4" value="-2.1699" spread="0.79822"/>
                    <measurement group_id="B5" value="-2.2642" spread="0.69731"/>
                    <measurement group_id="B6" value="-2.0978" spread="0.84652"/>
                    <measurement group_id="B7" value="-2.2305" spread="0.72892"/>
                    <measurement group_id="B8" value="-2.2021" spread="0.84645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trochanter BMD</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4938" spread="0.07793"/>
                    <measurement group_id="B2" value="0.4954" spread="0.06803"/>
                    <measurement group_id="B3" value="0.4844" spread="0.06610"/>
                    <measurement group_id="B4" value="0.4932" spread="0.07164"/>
                    <measurement group_id="B5" value="0.4879" spread="0.05653"/>
                    <measurement group_id="B6" value="0.5009" spread="0.06626"/>
                    <measurement group_id="B7" value="0.4900" spread="0.06824"/>
                    <measurement group_id="B8" value="0.4925" spread="0.06914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral Neck BMD</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5318" spread="0.07695"/>
                    <measurement group_id="B2" value="0.5258" spread="0.08147"/>
                    <measurement group_id="B3" value="0.5278" spread="0.07960"/>
                    <measurement group_id="B4" value="0.5348" spread="0.07154"/>
                    <measurement group_id="B5" value="0.5245" spread="0.06293"/>
                    <measurement group_id="B6" value="0.5411" spread="0.08051"/>
                    <measurement group_id="B7" value="0.5373" spread="0.07346"/>
                    <measurement group_id="B8" value="0.5327" spread="0.07712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral Neck BMD T-score</title>
          <description>BMD T-score is a comparison of an individual's BMD compared to &quot;normal&quot;. Also, BMD T-score is the standard deviation of the difference between measured BMD and that of the healthy young adult &quot;normal&quot;. The T-score scale is as follows: -1 and above=normal, -1 to -2.5=osteopenia (below normal and may lead to osteoporosis), and -2.5 and below=osteoporosis. Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.8683" spread="0.85505"/>
                    <measurement group_id="B2" value="-2.9358" spread="0.90523"/>
                    <measurement group_id="B3" value="-2.9135" spread="0.88448"/>
                    <measurement group_id="B4" value="-2.8360" spread="0.79487"/>
                    <measurement group_id="B5" value="-2.9501" spread="0.69920"/>
                    <measurement group_id="B6" value="-2.7652" spread="0.89454"/>
                    <measurement group_id="B7" value="-2.8077" spread="0.81618"/>
                    <measurement group_id="B8" value="-2.8594" spread="0.85690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dual-Energy X-Ray Absorptiometry (DXA) Measuring Apparatus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>QDR-4500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delphi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="118"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explorer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Existing Vertebral (Thoracic [Th4] -L4) Fractures</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="121"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fragility Fracture</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="104"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="97"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Osteoporosis Diagnosis Criteria 2012</title>
          <description>Data was available for 199, 66, 206, 67, 65, 201 and 66 participants in each treatment arm, respectively. YAM=young adult mean (lumbar spine: 20 to 44 years age range, proximal femur: 20 to 29 years age range).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fragility Fracture (Vertebrae or Proximal Femur)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="32"/>
                    <measurement group_id="B8" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fragility Fracture (Other and BMD&lt;YAM*80%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Fragility Fracture and BMD&lt;=YAM*70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="97"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 25-hydroxy Vitamin D (25-OH-D), Categorical</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Min - ≤14.9 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15.0 - ≤27.9 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="160"/>
                    <measurement group_id="B7" value="53"/>
                    <measurement group_id="B8" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28.0 ng/mL - ≤Max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 25-OH-D</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.55" spread="5.266"/>
                    <measurement group_id="B2" value="21.44" spread="5.423"/>
                    <measurement group_id="B3" value="21.46" spread="5.592"/>
                    <measurement group_id="B4" value="21.64" spread="5.427"/>
                    <measurement group_id="B5" value="21.17" spread="5.248"/>
                    <measurement group_id="B6" value="21.52" spread="5.121"/>
                    <measurement group_id="B7" value="20.58" spread="4.761"/>
                    <measurement group_id="B8" value="21.42" spread="5.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum C-telopeptide of Type 1 Collagen (CTX)</title>
          <description>Data was available for 199, 66, 205, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.444" spread="0.1660"/>
                    <measurement group_id="B2" value="0.460" spread="0.1855"/>
                    <measurement group_id="B3" value="0.426" spread="0.1776"/>
                    <measurement group_id="B4" value="0.421" spread="0.1437"/>
                    <measurement group_id="B5" value="0.497" spread="0.1867"/>
                    <measurement group_id="B6" value="0.417" spread="0.1592"/>
                    <measurement group_id="B7" value="0.399" spread="0.1613"/>
                    <measurement group_id="B8" value="0.434" spread="0.1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Bone-type Alkaline Phosphatase (BAP)</title>
          <description>Data was available for 199, 66, 205, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.91" spread="5.809"/>
                    <measurement group_id="B2" value="16.88" spread="8.617"/>
                    <measurement group_id="B3" value="15.83" spread="6.035"/>
                    <measurement group_id="B4" value="15.45" spread="5.024"/>
                    <measurement group_id="B5" value="17.17" spread="7.354"/>
                    <measurement group_id="B6" value="15.13" spread="5.164"/>
                    <measurement group_id="B7" value="15.13" spread="6.815"/>
                    <measurement group_id="B8" value="15.79" spread="6.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)</title>
          <description>Data was available for 199, 66, 205, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>mU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="427.1" spread="154.67"/>
                    <measurement group_id="B2" value="424.1" spread="144.89"/>
                    <measurement group_id="B3" value="422.1" spread="162.07"/>
                    <measurement group_id="B4" value="398.4" spread="127.54"/>
                    <measurement group_id="B5" value="444.7" spread="142.90"/>
                    <measurement group_id="B6" value="410.5" spread="142.09"/>
                    <measurement group_id="B7" value="395.0" spread="128.38"/>
                    <measurement group_id="B8" value="418.5" spread="148.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Procollagen 1 N-terminal Peptide (P1NP)</title>
          <description>Data was available for 198, 66, 206, 68, 64, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.79" spread="20.357"/>
                    <measurement group_id="B2" value="54.91" spread="27.552"/>
                    <measurement group_id="B3" value="50.89" spread="22.635"/>
                    <measurement group_id="B4" value="47.83" spread="17.120"/>
                    <measurement group_id="B5" value="53.43" spread="22.783"/>
                    <measurement group_id="B6" value="48.53" spread="20.366"/>
                    <measurement group_id="B7" value="46.04" spread="21.714"/>
                    <measurement group_id="B8" value="50.44" spread="21.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Type 1 Collagen Cross-linked N-telopeptide (NTX)</title>
          <description>Data was available for 199, 66, 206, 68, 65, 200 and 66 participants in each treatment arm, respectively.</description>
          <units>nmol BCE/mmol-CRE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.76" spread="26.169"/>
                    <measurement group_id="B2" value="61.04" spread="34.808"/>
                    <measurement group_id="B3" value="54.98" spread="23.928"/>
                    <measurement group_id="B4" value="53.77" spread="22.739"/>
                    <measurement group_id="B5" value="64.44" spread="29.535"/>
                    <measurement group_id="B6" value="54.48" spread="23.988"/>
                    <measurement group_id="B7" value="53.66" spread="23.911"/>
                    <measurement group_id="B8" value="56.24" spread="25.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study</title>
        <description>The change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
        <time_frame>Baseline and End of Study (up to Month 12)</time_frame>
        <population>Full Analysis Set (FAS), all randomized participants who received at least 1 dose of study drug, with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study</title>
          <description>The change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
          <population>Full Analysis Set (FAS), all randomized participants who received at least 1 dose of study drug, with data available for analyses.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="4.749"/>
                    <measurement group_id="O2" value="3.36" spread="4.332"/>
                    <measurement group_id="O3" value="4.11" spread="4.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was tested using t-test at a one-sided significance level of 2.5% and a non-inferiority margin (Δ) of 1.5%.</non_inferiority_desc>
            <p_value>0.1346</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>With a non-inferiority margin (Δ) of 1.5%.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was tested using t-test at a one-sided significance level of 2.5% and a non-inferiority margin (Δ) of 1.5%.</non_inferiority_desc>
            <p_value>0.6711</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>With a non-inferiority margin (Δ) of 1.5%.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.920</ci_lower_limit>
            <ci_upper_limit>0.001</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.617</ci_lower_limit>
            <ci_upper_limit>-0.794</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.166</ci_lower_limit>
            <ci_upper_limit>1.658</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) BMD Measured by DXA at Each Visit</title>
        <description>The change in BMD in each vertebra, L2 to L4, and the averages of L2 to L4 at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
        <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) BMD Measured by DXA at Each Visit</title>
          <description>The change in BMD in each vertebra, L2 to L4, and the averages of L2 to L4 at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=190, 62, 194, 61, 59, 181, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="4.211"/>
                    <measurement group_id="O2" value="1.73" spread="3.635"/>
                    <measurement group_id="O3" value="1.92" spread="4.124"/>
                    <measurement group_id="O4" value="2.40" spread="3.408"/>
                    <measurement group_id="O5" value="3.67" spread="4.841"/>
                    <measurement group_id="O6" value="2.70" spread="4.117"/>
                    <measurement group_id="O7" value="2.64" spread="4.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=178, 58, 180, 58, 55, 171, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="4.783"/>
                    <measurement group_id="O2" value="3.83" spread="4.227"/>
                    <measurement group_id="O3" value="3.53" spread="4.423"/>
                    <measurement group_id="O4" value="3.98" spread="3.784"/>
                    <measurement group_id="O5" value="5.04" spread="4.387"/>
                    <measurement group_id="O6" value="4.05" spread="4.518"/>
                    <measurement group_id="O7" value="4.38" spread="5.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=190, 62, 194, 61, 59, 181, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="4.749"/>
                    <measurement group_id="O2" value="3.82" spread="4.158"/>
                    <measurement group_id="O3" value="3.36" spread="4.332"/>
                    <measurement group_id="O4" value="3.93" spread="3.714"/>
                    <measurement group_id="O5" value="4.81" spread="4.383"/>
                    <measurement group_id="O6" value="4.11" spread="4.654"/>
                    <measurement group_id="O7" value="4.36" spread="5.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femur (Total Proximal Femur) BMD Measured by DXA at Each Visit</title>
        <description>The change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
        <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femur (Total Proximal Femur) BMD Measured by DXA at Each Visit</title>
          <description>The change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="2.782"/>
                    <measurement group_id="O2" value="0.91" spread="2.665"/>
                    <measurement group_id="O3" value="0.43" spread="2.666"/>
                    <measurement group_id="O4" value="0.54" spread="2.404"/>
                    <measurement group_id="O5" value="0.77" spread="2.401"/>
                    <measurement group_id="O6" value="0.78" spread="2.420"/>
                    <measurement group_id="O7" value="0.55" spread="2.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 58, 180, 59, 55, 172, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="3.316"/>
                    <measurement group_id="O2" value="1.32" spread="3.399"/>
                    <measurement group_id="O3" value="0.95" spread="3.233"/>
                    <measurement group_id="O4" value="1.15" spread="3.182"/>
                    <measurement group_id="O5" value="1.38" spread="3.013"/>
                    <measurement group_id="O6" value="1.45" spread="2.580"/>
                    <measurement group_id="O7" value="1.48" spread="2.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="3.288"/>
                    <measurement group_id="O2" value="1.30" spread="3.309"/>
                    <measurement group_id="O3" value="0.89" spread="3.172"/>
                    <measurement group_id="O4" value="1.15" spread="3.131"/>
                    <measurement group_id="O5" value="1.33" spread="2.948"/>
                    <measurement group_id="O6" value="1.45" spread="2.565"/>
                    <measurement group_id="O7" value="1.39" spread="2.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femur (Trochanter) BMD Measured by DXA at Each Visit</title>
        <description>The change in BMD in the femur (trochanter) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
        <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femur (Trochanter) BMD Measured by DXA at Each Visit</title>
          <description>The change in BMD in the femur (trochanter) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="4.854"/>
                    <measurement group_id="O2" value="1.57" spread="3.832"/>
                    <measurement group_id="O3" value="0.70" spread="4.324"/>
                    <measurement group_id="O4" value="0.80" spread="3.500"/>
                    <measurement group_id="O5" value="1.46" spread="3.495"/>
                    <measurement group_id="O6" value="1.09" spread="3.141"/>
                    <measurement group_id="O7" value="0.53" spread="4.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 58, 180, 59, 55, 172, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="6.007"/>
                    <measurement group_id="O2" value="1.80" spread="4.030"/>
                    <measurement group_id="O3" value="1.36" spread="4.632"/>
                    <measurement group_id="O4" value="1.66" spread="4.095"/>
                    <measurement group_id="O5" value="2.47" spread="4.129"/>
                    <measurement group_id="O6" value="1.94" spread="3.722"/>
                    <measurement group_id="O7" value="1.90" spread="4.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="5.938"/>
                    <measurement group_id="O2" value="1.67" spread="3.951"/>
                    <measurement group_id="O3" value="1.35" spread="4.551"/>
                    <measurement group_id="O4" value="1.64" spread="4.038"/>
                    <measurement group_id="O5" value="2.42" spread="4.005"/>
                    <measurement group_id="O6" value="1.94" spread="3.661"/>
                    <measurement group_id="O7" value="1.85" spread="4.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femur (Femoral Neck) BMD Measured by DXA at Each Visit</title>
        <description>The change in BMD in the femur (femoral neck) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
        <time_frame>Baseline and Month 6, Month 12, and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femur (Femoral Neck) BMD Measured by DXA at Each Visit</title>
          <description>The change in BMD in the femur (femoral neck) at each visit relative to baseline. DXA is a means of measuring BMD through x-ray.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="3.406"/>
                    <measurement group_id="O2" value="0.90" spread="3.903"/>
                    <measurement group_id="O3" value="0.71" spread="4.205"/>
                    <measurement group_id="O4" value="0.49" spread="3.804"/>
                    <measurement group_id="O5" value="1.01" spread="3.732"/>
                    <measurement group_id="O6" value="0.57" spread="3.572"/>
                    <measurement group_id="O7" value="0.67" spread="2.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 58, 180, 59, 55, 172, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="4.010"/>
                    <measurement group_id="O2" value="0.78" spread="4.302"/>
                    <measurement group_id="O3" value="1.34" spread="4.687"/>
                    <measurement group_id="O4" value="1.47" spread="4.055"/>
                    <measurement group_id="O5" value="1.00" spread="3.799"/>
                    <measurement group_id="O6" value="1.24" spread="3.492"/>
                    <measurement group_id="O7" value="0.56" spread="4.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=189, 62, 194, 61, 59, 180, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="4.017"/>
                    <measurement group_id="O2" value="0.99" spread="4.451"/>
                    <measurement group_id="O3" value="1.30" spread="4.638"/>
                    <measurement group_id="O4" value="1.55" spread="4.009"/>
                    <measurement group_id="O5" value="0.96" spread="3.754"/>
                    <measurement group_id="O6" value="1.29" spread="3.578"/>
                    <measurement group_id="O7" value="0.52" spread="3.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Turnover Marker Serum Creatinine (CTX) at Each Visit</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Turnover Marker Serum Creatinine (CTX) at Each Visit</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=199, 66, 204, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.02" spread="27.396"/>
                    <measurement group_id="O2" value="-17.42" spread="27.978"/>
                    <measurement group_id="O3" value="-15.53" spread="26.107"/>
                    <measurement group_id="O4" value="-18.80" spread="25.956"/>
                    <measurement group_id="O5" value="-33.52" spread="24.667"/>
                    <measurement group_id="O6" value="-24.74" spread="28.675"/>
                    <measurement group_id="O7" value="-19.34" spread="28.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=193, 63, 193, 65, 60, 184, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.79" spread="25.044"/>
                    <measurement group_id="O2" value="-29.29" spread="22.794"/>
                    <measurement group_id="O3" value="-24.80" spread="31.118"/>
                    <measurement group_id="O4" value="-28.76" spread="28.409"/>
                    <measurement group_id="O5" value="-36.36" spread="23.925"/>
                    <measurement group_id="O6" value="-31.30" spread="28.196"/>
                    <measurement group_id="O7" value="-29.94" spread="26.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=188, 61, 190, 60, 58, 178, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.42" spread="22.926"/>
                    <measurement group_id="O2" value="-36.97" spread="29.126"/>
                    <measurement group_id="O3" value="-24.39" spread="38.994"/>
                    <measurement group_id="O4" value="-35.33" spread="24.539"/>
                    <measurement group_id="O5" value="-44.28" spread="24.390"/>
                    <measurement group_id="O6" value="-37.65" spread="28.327"/>
                    <measurement group_id="O7" value="-35.13" spread="25.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=185, 60, 185, 59, 55, 175, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.44" spread="26.256"/>
                    <measurement group_id="O2" value="-33.61" spread="27.438"/>
                    <measurement group_id="O3" value="-16.75" spread="83.047"/>
                    <measurement group_id="O4" value="-27.99" spread="32.106"/>
                    <measurement group_id="O5" value="-42.94" spread="24.912"/>
                    <measurement group_id="O6" value="-34.50" spread="33.805"/>
                    <measurement group_id="O7" value="-30.97" spread="32.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 55, 178, 59, 54, 170, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.98" spread="28.051"/>
                    <measurement group_id="O2" value="-32.11" spread="32.662"/>
                    <measurement group_id="O3" value="-16.42" spread="64.139"/>
                    <measurement group_id="O4" value="-23.68" spread="44.492"/>
                    <measurement group_id="O5" value="-40.00" spread="26.613"/>
                    <measurement group_id="O6" value="-31.56" spread="36.239"/>
                    <measurement group_id="O7" value="-24.62" spread="37.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=199, 66, 204, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.61" spread="28.275"/>
                    <measurement group_id="O2" value="-29.94" spread="36.896"/>
                    <measurement group_id="O3" value="-16.27" spread="60.895"/>
                    <measurement group_id="O4" value="-24.33" spread="43.256"/>
                    <measurement group_id="O5" value="-39.58" spread="26.203"/>
                    <measurement group_id="O6" value="-32.33" spread="35.959"/>
                    <measurement group_id="O7" value="-26.28" spread="36.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Turnover Marker Serum Bone-type Alkaline Phosphatase (BAP) at Each Visit</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Turnover Marker Serum Bone-type Alkaline Phosphatase (BAP) at Each Visit</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=199, 66, 205, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.04" spread="11.881"/>
                    <measurement group_id="O2" value="-2.93" spread="13.365"/>
                    <measurement group_id="O3" value="-2.61" spread="11.351"/>
                    <measurement group_id="O4" value="-3.61" spread="12.135"/>
                    <measurement group_id="O5" value="-4.16" spread="13.493"/>
                    <measurement group_id="O6" value="-3.69" spread="13.142"/>
                    <measurement group_id="O7" value="-2.44" spread="10.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=193, 63, 193, 65, 60, 184, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.56" spread="15.047"/>
                    <measurement group_id="O2" value="-13.64" spread="18.499"/>
                    <measurement group_id="O3" value="-13.31" spread="17.846"/>
                    <measurement group_id="O4" value="-15.99" spread="19.091"/>
                    <measurement group_id="O5" value="-24.85" spread="14.835"/>
                    <measurement group_id="O6" value="-17.52" spread="18.589"/>
                    <measurement group_id="O7" value="-13.83" spread="24.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=188, 61, 190, 60, 58, 178, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.66" spread="19.087"/>
                    <measurement group_id="O2" value="-20.92" spread="23.433"/>
                    <measurement group_id="O3" value="-17.93" spread="21.202"/>
                    <measurement group_id="O4" value="-23.90" spread="18.990"/>
                    <measurement group_id="O5" value="-31.06" spread="14.859"/>
                    <measurement group_id="O6" value="-24.06" spread="19.744"/>
                    <measurement group_id="O7" value="-23.80" spread="18.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=185, 61, 185, 59, 55, 175, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.84" spread="17.700"/>
                    <measurement group_id="O2" value="-25.23" spread="24.949"/>
                    <measurement group_id="O3" value="-22.48" spread="22.233"/>
                    <measurement group_id="O4" value="-28.00" spread="20.334"/>
                    <measurement group_id="O5" value="-33.15" spread="16.226"/>
                    <measurement group_id="O6" value="-28.70" spread="19.536"/>
                    <measurement group_id="O7" value="-25.84" spread="21.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 55, 178, 59, 54, 170, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.53" spread="20.506"/>
                    <measurement group_id="O2" value="-29.23" spread="22.721"/>
                    <measurement group_id="O3" value="-24.91" spread="21.537"/>
                    <measurement group_id="O4" value="-30.51" spread="17.290"/>
                    <measurement group_id="O5" value="-38.06" spread="15.153"/>
                    <measurement group_id="O6" value="-29.58" spread="21.560"/>
                    <measurement group_id="O7" value="-27.74" spread="21.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=199, 66, 205, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.34" spread="21.428"/>
                    <measurement group_id="O2" value="-26.27" spread="24.287"/>
                    <measurement group_id="O3" value="-23.11" spread="21.553"/>
                    <measurement group_id="O4" value="-27.21" spread="19.932"/>
                    <measurement group_id="O5" value="-33.94" spread="18.140"/>
                    <measurement group_id="O6" value="-27.52" spread="21.962"/>
                    <measurement group_id="O7" value="-27.08" spread="21.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Turnover Marker Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Each Visit</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Turnover Marker Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Each Visit</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=199, 66, 205, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.38" spread="17.664"/>
                    <measurement group_id="O2" value="-17.26" spread="20.728"/>
                    <measurement group_id="O3" value="-17.49" spread="19.406"/>
                    <measurement group_id="O4" value="-21.05" spread="17.749"/>
                    <measurement group_id="O5" value="-30.75" spread="19.626"/>
                    <measurement group_id="O6" value="-25.20" spread="19.726"/>
                    <measurement group_id="O7" value="-22.06" spread="20.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=193, 63, 193, 65, 60, 184, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.27" spread="17.105"/>
                    <measurement group_id="O2" value="-25.46" spread="18.567"/>
                    <measurement group_id="O3" value="-23.85" spread="22.714"/>
                    <measurement group_id="O4" value="-27.46" spread="19.454"/>
                    <measurement group_id="O5" value="-33.70" spread="20.735"/>
                    <measurement group_id="O6" value="-28.36" spread="20.299"/>
                    <measurement group_id="O7" value="-27.13" spread="22.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=188, 61, 190, 60, 58, 178, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.48" spread="17.702"/>
                    <measurement group_id="O2" value="-29.15" spread="21.223"/>
                    <measurement group_id="O3" value="-23.87" spread="27.077"/>
                    <measurement group_id="O4" value="-29.38" spread="20.340"/>
                    <measurement group_id="O5" value="-37.16" spread="18.794"/>
                    <measurement group_id="O6" value="-31.49" spread="21.748"/>
                    <measurement group_id="O7" value="-30.67" spread="21.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=185, 61, 185, 59, 55, 175, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.64" spread="19.734"/>
                    <measurement group_id="O2" value="-25.82" spread="24.762"/>
                    <measurement group_id="O3" value="-19.44" spread="45.595"/>
                    <measurement group_id="O4" value="-24.78" spread="22.657"/>
                    <measurement group_id="O5" value="-32.78" spread="21.561"/>
                    <measurement group_id="O6" value="-28.83" spread="24.971"/>
                    <measurement group_id="O7" value="-29.71" spread="23.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 55, 178, 59, 54, 170, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.91" spread="20.628"/>
                    <measurement group_id="O2" value="-23.70" spread="25.425"/>
                    <measurement group_id="O3" value="-13.25" spread="63.783"/>
                    <measurement group_id="O4" value="-20.54" spread="26.613"/>
                    <measurement group_id="O5" value="-31.03" spread="22.287"/>
                    <measurement group_id="O6" value="-24.31" spread="26.832"/>
                    <measurement group_id="O7" value="-23.21" spread="25.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=199, 66, 205, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.76" spread="20.602"/>
                    <measurement group_id="O2" value="-22.93" spread="26.532"/>
                    <measurement group_id="O3" value="-13.86" spread="60.015"/>
                    <measurement group_id="O4" value="-21.29" spread="26.141"/>
                    <measurement group_id="O5" value="-31.97" spread="21.945"/>
                    <measurement group_id="O6" value="-25.93" spread="26.283"/>
                    <measurement group_id="O7" value="-24.46" spread="25.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Turnover Marker Serum Procollagen 1 N-terminal Peptide (P1NP) at Each Visit</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Turnover Marker Serum Procollagen 1 N-terminal Peptide (P1NP) at Each Visit</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule. Blood samples were to be collected at about the same time of the day, as far as possible, throughout the study.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=196, 66, 206, 68, 64, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.55" spread="17.134"/>
                    <measurement group_id="O2" value="-9.08" spread="16.765"/>
                    <measurement group_id="O3" value="-7.70" spread="15.206"/>
                    <measurement group_id="O4" value="-9.73" spread="16.472"/>
                    <measurement group_id="O5" value="-13.68" spread="16.892"/>
                    <measurement group_id="O6" value="-9.86" spread="14.908"/>
                    <measurement group_id="O7" value="-10.07" spread="15.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=192, 63, 194, 64, 59, 184, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.59" spread="19.379"/>
                    <measurement group_id="O2" value="-32.19" spread="27.464"/>
                    <measurement group_id="O3" value="-29.09" spread="26.955"/>
                    <measurement group_id="O4" value="-34.30" spread="20.730"/>
                    <measurement group_id="O5" value="-45.91" spread="22.176"/>
                    <measurement group_id="O6" value="-36.80" spread="29.014"/>
                    <measurement group_id="O7" value="-34.14" spread="24.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=187, 61, 191, 60, 57, 178, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.83" spread="22.450"/>
                    <measurement group_id="O2" value="-39.51" spread="27.766"/>
                    <measurement group_id="O3" value="-33.02" spread="35.354"/>
                    <measurement group_id="O4" value="-39.21" spread="23.522"/>
                    <measurement group_id="O5" value="-51.40" spread="18.641"/>
                    <measurement group_id="O6" value="-42.21" spread="26.918"/>
                    <measurement group_id="O7" value="-40.90" spread="26.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=184, 61, 186, 59, 54, 175, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.82" spread="29.820"/>
                    <measurement group_id="O2" value="-34.80" spread="29.523"/>
                    <measurement group_id="O3" value="-27.74" spread="38.273"/>
                    <measurement group_id="O4" value="-36.41" spread="24.862"/>
                    <measurement group_id="O5" value="-46.14" spread="21.531"/>
                    <measurement group_id="O6" value="-38.32" spread="30.139"/>
                    <measurement group_id="O7" value="-32.09" spread="36.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=180, 55, 179, 59, 53, 170, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.90" spread="31.614"/>
                    <measurement group_id="O2" value="-35.65" spread="27.158"/>
                    <measurement group_id="O3" value="-25.32" spread="36.833"/>
                    <measurement group_id="O4" value="-31.80" spread="28.472"/>
                    <measurement group_id="O5" value="-42.75" spread="24.603"/>
                    <measurement group_id="O6" value="-31.33" spread="33.403"/>
                    <measurement group_id="O7" value="-29.11" spread="35.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=198, 66, 206, 68, 64, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.93" spread="31.952"/>
                    <measurement group_id="O2" value="-32.03" spread="31.584"/>
                    <measurement group_id="O3" value="-25.51" spread="35.324"/>
                    <measurement group_id="O4" value="-30.67" spread="27.441"/>
                    <measurement group_id="O5" value="-40.82" spread="24.646"/>
                    <measurement group_id="O6" value="-31.74" spread="31.892"/>
                    <measurement group_id="O7" value="-29.13" spread="34.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Turnover Marker Urine Type 1 Collagen Cross-linked N-telopeptide (NTX) at Each Visit</title>
        <description>Urine samples for urine bone turnover markers were collected at specified visits according to the study schedule. Urine samples were to be collected at about the same time of the day, as far as possible, throughout the study. Urine NTX was corrected by creatinine value.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9 and 12 and End of Study (Last observation carried forward at Month 12)</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Turnover Marker Urine Type 1 Collagen Cross-linked N-telopeptide (NTX) at Each Visit</title>
          <description>Urine samples for urine bone turnover markers were collected at specified visits according to the study schedule. Urine samples were to be collected at about the same time of the day, as far as possible, throughout the study. Urine NTX was corrected by creatinine value.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=199, 66, 206, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.73" spread="29.296"/>
                    <measurement group_id="O2" value="-11.79" spread="38.228"/>
                    <measurement group_id="O3" value="-12.42" spread="35.178"/>
                    <measurement group_id="O4" value="-17.15" spread="40.458"/>
                    <measurement group_id="O5" value="-29.81" spread="29.087"/>
                    <measurement group_id="O6" value="-16.42" spread="39.131"/>
                    <measurement group_id="O7" value="-12.64" spread="42.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=193, 63, 194, 65, 60, 184, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.94" spread="30.360"/>
                    <measurement group_id="O2" value="-22.32" spread="35.861"/>
                    <measurement group_id="O3" value="-15.64" spread="39.676"/>
                    <measurement group_id="O4" value="-20.24" spread="37.412"/>
                    <measurement group_id="O5" value="-31.27" spread="28.984"/>
                    <measurement group_id="O6" value="-22.60" spread="35.284"/>
                    <measurement group_id="O7" value="-20.70" spread="37.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=188, 61, 191, 60, 58, 178, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.00" spread="35.405"/>
                    <measurement group_id="O2" value="-29.69" spread="37.178"/>
                    <measurement group_id="O3" value="-7.96" spread="52.202"/>
                    <measurement group_id="O4" value="-19.51" spread="41.804"/>
                    <measurement group_id="O5" value="-36.99" spread="28.317"/>
                    <measurement group_id="O6" value="-20.79" spread="40.913"/>
                    <measurement group_id="O7" value="-20.92" spread="38.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=185, 61, 186, 59, 55, 175, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.97" spread="38.541"/>
                    <measurement group_id="O2" value="-17.23" spread="38.383"/>
                    <measurement group_id="O3" value="-7.71" spread="50.697"/>
                    <measurement group_id="O4" value="-19.48" spread="36.149"/>
                    <measurement group_id="O5" value="-31.25" spread="26.172"/>
                    <measurement group_id="O6" value="-15.90" spread="47.103"/>
                    <measurement group_id="O7" value="-14.07" spread="46.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=181, 55, 179, 59, 54, 170, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.64" spread="37.715"/>
                    <measurement group_id="O2" value="-27.45" spread="33.172"/>
                    <measurement group_id="O3" value="-4.66" spread="61.863"/>
                    <measurement group_id="O4" value="-24.87" spread="34.422"/>
                    <measurement group_id="O5" value="-31.74" spread="34.664"/>
                    <measurement group_id="O6" value="-17.68" spread="55.937"/>
                    <measurement group_id="O7" value="-21.94" spread="42.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=199, 66, 206, 68, 65, 200, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.30" spread="37.274"/>
                    <measurement group_id="O2" value="-25.83" spread="32.786"/>
                    <measurement group_id="O3" value="-4.72" spread="59.237"/>
                    <measurement group_id="O4" value="-23.18" spread="35.863"/>
                    <measurement group_id="O5" value="-31.55" spread="35.083"/>
                    <measurement group_id="O6" value="-21.06" spread="53.671"/>
                    <measurement group_id="O7" value="-24.14" spread="42.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Non-traumatic Vertebral Fractures (Including the Worsening of Pre-existing Fractures)</title>
        <description>New non-traumatic vertebral fractures were identified by interpretable X-ray images of 13 vertebrae from the fourth thoracic to the fourth lumbar vertebra. A Central Review Committee member for X-ray determined the presence or absence of new vertebral fractures, the number of new fractures, the presence or absence of worsening pre-existing vertebral fractures, and the number of worsened fractures. The assessment of new vertebral fractures and the worsening of pre-existing vertebral fractures was semiquantitative. The X-ray images were visually inspected and classified into normal (Grade 0), mild deformation (Grade 1), moderate deformation (Grade 2), or severe deformation (Grade 3). If the assessment of any vertebra became worse by at least 1 grade after starting the treatment, its height was measured. A new vertebral fracture or a worsening pre-existing vertebral fracture was concluded if the vertebra’s height was reduced from the baseline by at least 20% and by at least 4 mm.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
            <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O2">
            <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O3">
            <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O4">
            <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O5">
            <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O6">
            <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
          <group group_id="O7">
            <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
            <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Non-traumatic Vertebral Fractures (Including the Worsening of Pre-existing Fractures)</title>
          <description>New non-traumatic vertebral fractures were identified by interpretable X-ray images of 13 vertebrae from the fourth thoracic to the fourth lumbar vertebra. A Central Review Committee member for X-ray determined the presence or absence of new vertebral fractures, the number of new fractures, the presence or absence of worsening pre-existing vertebral fractures, and the number of worsened fractures. The assessment of new vertebral fractures and the worsening of pre-existing vertebral fractures was semiquantitative. The X-ray images were visually inspected and classified into normal (Grade 0), mild deformation (Grade 1), moderate deformation (Grade 2), or severe deformation (Grade 3). If the assessment of any vertebra became worse by at least 1 grade after starting the treatment, its height was measured. A new vertebral fracture or a worsening pre-existing vertebral fracture was concluded if the vertebra’s height was reduced from the baseline by at least 20% and by at least 4 mm.</description>
          <population>FAS, all randomized participants who received at least 1 dose of study drug, with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="178"/>
                <count group_id="O7" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="1.1"/>
                    <measurement group_id="O7" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="97.9"/>
                    <measurement group_id="O4" value="96.8"/>
                    <measurement group_id="O5" value="96.6"/>
                    <measurement group_id="O6" value="98.9"/>
                    <measurement group_id="O7" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to 30 days past last dose of study drug (Up to 13 Months)</time_frame>
      <desc>At each visit the investigator documented any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of relation to study treatment. AEs were monitored until the participant recovered or investigator judged no further follow-up was needed.</desc>
      <group_list>
        <group group_id="E1">
          <title>NE-58095 IR 2.5 mg Once Daily on Awakening</title>
          <description>NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E2">
          <title>NE-58095 DR 25 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E3">
          <title>NE-58095 DR 25 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E4">
          <title>NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E5">
          <title>NE-58095 DR 37.5 mg Once Monthly on Awakening</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E6">
          <title>NE-58095 DR 37.5 mg Once Monthly Following Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
        <group group_id="E7">
          <title>NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast</title>
          <description>NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <description>One treatment-emergent death occurred during treatment in NE-58095 DR 37.5 mg Once Monthly Following Breakfast group and is not related to study drug.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Soft tissue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="138" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The collaborator company name EA Pharma Co., Ltd. has been changed from 1st April 2016. The legacy name was Ajinomoto Pharmaceutics Co., Ltd.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

